SEC Filings
MoonLake Skipped A $50 Million Loan Tranche, Leaving Its Next Borrowing Up To Lenders
The biotech's cash fell to $498.5 million as an undrawn $50.0 million tranche folded into a lender-approval tranche now up to $250.0 million.
MoonLake Immunotherapeutics (MLTX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The biotech's cash fell to $498.5 million as an undrawn $50.0 million tranche folded into a lender-approval tranche now up to $250.0 million.
SEC Filings
The biotech says $498.5 million in cash lasts to mid-2028, and up to $400 million more is available through a Hercules Capital debt facility.
SEC Filings
The biologics license application covers moderate-to-severe hidradenitis suppurativa in adults and adolescents as young as 12.